Neurocrine Biosciences Inc. is solely focused on preparing for a June launch of its tardive dyskinesia drug Ingrezza (valbenazine) now that the hurdle of a US FDA advisory committee review has been removed.
Neurocrine execs said they have no reason to believe valbenazine will not be approved by the new drug application's (NDA)...






